Dr Daniel Tillett appointed CEO of Race Oncology
Filed with ASX · · 3 pages · English
Earlier from Racura Oncology
- RC220 Meets Quality Specifications
- Impressive Bisantrene Phase 2 AML Clinical Results
- Trading Halt
- RC220 Peripheral Infusion Safety Confirmed
- RC220 Toxicology and Safety Pharmacology Studies Initiated
Later from Racura Oncology
- Updated Strategy and Investor Presentation
- Bonus Options Prospectus
- December 2023 Preclinical & Clinical Program Update
- Race Receives $4.0m R&D Tax Refund for Financial Year 2023
- S&P DJI Announces March 2024 Quarterly Rebalance
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology